Mark Kontny Joins Board
Mark Kontny named newest Board Member at Grand River Aseptic Manufacturing.
The Grand River Aseptic Manufacturing (“GRAM”) board of directors elected Mark Kontny to join the ranks as the newest board member. Mark brings thirty years of pharmaceutical experience to GRAM’s Board of Directors.
Before coming to GRAM, Mark recently served as President, Pharmaceutical Development Services & Chief Scientific Officer for Patheon. Based in North Carolina, Patheon is a large pharmaceutical development and manufacturing company with revenues approaching $1.0 billion. Previously, Mark served as Divisional Vice President for Abbott Laboratories, responsible for divisional staffs in Illinois, Massachusetts, Germany and Singapore. Earlier in his career, Mark spent close to ten years at Boehringer Ingelheim, a global pharmaceutical company, working with the pre-formulation, formulation and manufacturing of different dosage forms. He then moved on to become Senior Director at Pfizer and helped develop small molecules and biologics in both solid-dose and parenteral (injectable) forms. After leaving Pfizer, Mark spent time working with a biotech start-up, but went back to large pharma at Abbott before moving to Patheon. Mark’s experience and background with both large pharma and startups will help steer GRAM towards growth and aid in the continued success that the company has accomplished in its five years of existence.
Tom Ross, GRAM president and CEO, noted “We look forward to the leadership that Mark will provide as a GRAM Board Member. His deep industry experience and knowledge of the pharmaceutical industry, specifically the parenteral space, will contribute to great decisions for the future. We have already benefitted from Mark’s counsel and we are happy to welcome him to the board.”